Faculty

32 1a 2a

61 16

Katharine J Bar, MD

Associate Professor of Medicine (Infectious Diseases)

7 5f

Department: Medicine

4 1 23

1f Graduate Group Affiliations 8

Cell and Molecular Biology

46 Contact information
44

502 D Johnson Pavilion
3a 3610 Hamilton Walk
Philadelphia, PA 19104-6073

30 Office: (215) 573-8497
34 Fax: (215) 349-5111
24

Email:
bark@pennmedicine.upenn.edu

4 3 3 3 2 4 b 1f

13 Education:
21 7 BA 35 (Biochemistry and African History, Honors) c
3e Northwestern University, Evanston, IL, 1997.
21 7 MD c
4e University of Iowa College of Medicine, Iowa City, IA, 2002.
c

3 3 3 3 92 Permanent link
2 29

b6 > Perelman School of Medicine > Faculty > Details a

1e 1d

Description of Clinical Expertise

39 HIV care, general infectious disease care
71

Description of Research Expertise

74 The Bar Lab studies novel approaches to HIV prevention and cure. Our current research focuses on:
7d (i) characterizing the viral dynamics and host immune responses during virus suppression and treatment interruption,
5f (ii) developing NHP models that faithfully recapitulate HIV-1 latency and rebound, and
35 (iii) developing antibody-based interventions.
e 29

Selected Publications

18c Pampena MB, Samer S, Viox EG, Nguyen K, Deleage C, Kuri-Cervantes L, Regan J, Wu VH, Docken S, Safrit JT, Bar KJ, Keele BF, Davenport MP, Paiardini M, Betts MR. : Therapeutic CD8+ T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound. Proc Natl Acad Sci U S A. 122(33), Aug 2025.

295 Karuna S, Laher F, Dadabhai S, Yu PC, Grove D, Orrell C, Makhema J, Hosseinipour MC, Mathew CA, Brumskine W, Mgodi N, Andrew P, Gama L, Karg C, Broder G, Baepanye K, Lucas J, Andrasik M, Takuva S, Villaran M, Takalani A, Tressler R, Soto-Torres L, Woodward Davis AS, Dhai A, Sanne IM, Cohen MS, Corey L, Gray G, deCamp AC, Bar KJ: Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data. J Int AIDS Soc 28(6): e26495, June 2025.

18b Pahus MH, Zheng Y, Olefsky M, Gunst JD, Tebas P, Taiwo B, Søgaard OS, Peluso MJ, Lie Y, Reeves JD, Petropoulos CJ, Caskey M, Bar KJ.: Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies. J Infect Dis doi: 10.1093/infdis/jiae486, Feb 2025.

1cc Mainou E, Berendam SJ, Obregon-Perko V, Uffman EA, Phan CT, Shaw GM, Bar KJ, Kumar MR, Fray EJ, Siliciano JM, Siliciano RF, Silvestri G, Permar SR, Fouda GG, McCarthy J, Chahroudi A, Conway JM, Chan C.: Assessing the impact of autologous virus neutralizing antibodies on viral rebound time in postnatally SHIV-infected ART-treated infant rhesus macaques. Epidemics 48(100780), Sep 2024.

1db Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL: CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J Clin Invest 134(9): e181576, May 2024.

17a Whitehill GD, Joy J, Marino FE, Krause R, Mallick S, Courtney H, Park K, Carey J, Hoh R, Hartig H, Pae V, Sarvadhavabhatla S, Donaire S, Deeks SG, Lynch RM, Lee SA, Bar KJ: Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1. J Clin Invest 134(11), April 2024.

1fb Miner MD, deCamp A, Grunenberg N, De Rosa SC, Fiore-Gartland A, Bar K, Spearman P, Allen M, Yu PC, Manso B, Frahm N, Kalams S, Baden L, Keefer MC, Scott HM, Novak R, Van Tieu H, Tomaras GD, Kublin JG, McElrath MJ, Corey L, Frank I; HVTN 085 Study Team: Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial. EBioMedicine 100: 104987, Feb 2024.

35b Maurine D. Miner, Allan deCamp, Nicole Grunenberg, Stephen C. De Rosa, Andrew Fiore-Gartland, Katherine Bar, Paul Spearman, Mary Allen, Pei-Chun Yu, Bryce Manso, Nicole Frahm, Spyros Kalams, Lindsey Baden, Michael C. Keefer, Hyman M. Scott, Richard Novak, Hong Van Tieu, Georgia D. Tomaras, James G. Kublin, M. Juliana McElrath, Lawrence Corey, Ian Frank, Artur Kalichman, Paul Edlefsen, Mary Enama, John Hural, Renee Holt, Debora Dunbar, Dave Crawford, Ian Maki, Jan Johannessen, Scharla Estep, Yevgeny Grigoriev, Tamra Madenwald, Marianne Hansen, Drienna Holman, Ramey Fair, Genevieve Meyer, Anya Luke-Kilolam: Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial. eBioMedicine 100, Jan 2024.

263 Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S.: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun 14(1): 8299, Dec 2023.

17d Docken SS, McCormick K, Pampena MB, Samer S, Lindemuth E, Pinkevych M, Viox EG, Wu Y, Schlub TE, Cromer D, Keele BF, Paiardini M, Betts MR, Bar KJ, Davenport MP.: Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency. PLoS Pathog 19(11): e1011755, Nov 2023.

2c

7 1d

2c back to top
26 Last updated: 11/12/2025
34 The Trustees of the University of Pennsylvania c

1 49 2 2 1a 32 34